BresoTEC
BresoTEC has developed a proprietary acoustic and movement-based AI analysis platform that transforms the precision of a sleep laboratory in to a simple, cordless technology for home use. BresoTEC has completed development and will begin clinical trials early in the new year. Use of funds raised are for scale up of marketing, selling and regulatory manufacturing costs for the US market, development of the second version of the BresoDX home sleep test and scaling costs.
Presenter: Peter Bloch, CEO
Read More
ChipCare
ChipCare is a pre-revenue biotech company based in Toronto. We are in late stage development of a novel point-of-care in-vitro diagnostic platform for the differential diagnosis of infectious diseases and health monitoring. The platform includes an analyzer and single use cartridges which contain test specific reagents. The platform is intended for use in community clinics, congregate care residences, chain pharmacies, under-serviced communities etc. and provides a test result in ~ 30 minutes. This enables health care workers to provide diagnosis and treatment in a single visit, minimizing the spread of disease and delays in treatment. We expect to go to market with our initial STI assay in mid-2022.
Presenter: Jeffrey Weisberg, Chief Executive Officer and President
Read More
Curiato
Curiato is a digital health platform that is leveraging biosensing and AI to deliver patient data and insights directly from the surface of the bed to power an ecosystem of applications such as pressure injuries, heart failure, infectious disease, burns, patient safety and more. One device, multiple clinical software applications. Curiato is post revenue with successful clinical pilots, publications and Health Canada licensed. Curiatio is raising Series A capital to support US market entry, sales & marketing, and creation of additional clinical software applications.
Presenter: Moazam Khan, Co-Founder & CEO
Read More
DNAMx
DNAMx is a cross-border molecular diagnostics start-up company being spun out of University Health Network. Scientific co-founders from Princess Margaret Cancer Research Institute, Daniel De Carvalho (Interim CSO) and Scott Bratman (CEO), have joined forces with serial entrepreneurs, Anne-Renee Hartman (CMO), David Scheer (Board Chair), and Maneesh Jain (Board Member), to commercialized cutting-edge liquid biopsy technology for cancer detection and management. Building on multiple high-impact publications in Nature and Nature Medicine, DNAMx is now raising a large Series A financing round to achieve ambitious milestones aimed at bringing the technology into the clinic.
Hear more from this company during the Early Technology Showcase.
Presenter: Scott Bratman, Founder & CEO
Read More
Huron Digital Pathology
With a first-of-its-kind, AI-enabled image search engine called Lagotto, Huron Digital Pathology is revolutionizing how pathologists access the vast knowledge contained in the world’s pathology reports, hospital records, and clinical data, to drive efficiency and reduce diagnostic error. We just gained our first high profile customer for Lagotto in the US and are beginning to generate recurring software revenue. We are actively engaging with large hospitals and institutions keen to benefit from our solution. We are raising a Series A round to scale our sales efforts, expand our product portfolio and achieve regulatory approvals.
Presenter: Patrick Myles, Chief Executive Officer
Read More
MY01
MY01 Inc. is on a mission to empower healthcare professionals with the ability to pre-empt severe medical conditions thereby improving patient outcomes. We are commercial and saving limbs with our MY01 Continuous Intracompartment Pressure Monitor.
Presenter: Charles Allan, CEO
Read More
Oncoustics
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Oncoustics applies AI to raw ultrasound signals from readily available handheld ultrasound devices to rapidly differentiate healthy versus diseased tissues. Oncoustics is a clinical-stage company with partnerships with several ultrasound OEMs, and FDA pre-sub and trials this year. Oncoustics is raising Series A capital to bring the first product to market (FDA clearance), and continue growing the data library for new indications, as well as grow the team.
Presenter: Ahmed El Kaffas, Founder
Read More
Rna Diagnostics
Rna Diagnostics is a clinical-stage company developing it’s first product, a proprietary diagnostic test for breast cancer therapy response measurement. Our test will indicate to doctors, early in treatment, which patients will receive a survival benefit and which patients will not. This test will help address the $60 billion that is spent each year on cancer drugs that are not working for a majority of patients.
Presenter: Jeremy Bridge-Cook, President & CEO
Read More
VitalTracer
VitalTracer is a start-up whose focus is on healthcare in the domain of personalized medicine. We aim to create a platform for those who need to improve or manage health with a convenient and non-invasive solution. VitalTracer has raised about 1 million in non-dilutive financing and is currently boot-strapping. We will open our seed round in summer 2021 which will cover our expenses of Research and Development, Regulatory clearance for Health Canada and FDA, manufacturing and clinical validation.
Presenter: Azadeh Dastmalchi, CEO
Read More
